Regeneron Shows Proof Of Concept For Novel Cholesterol Drug

An investigational hypolipemic product from Regeneron Pharmaceuticals with a novel mechanism of action appears to have great promise when used in addition to current therapies in familial hypercholesterolemia patients, suggest early data from a small study, but many questions remain.

More from Clinical Trials

More from R&D